PharmiNews

The Directory of Pharma Companies and News

Novartis

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2014, the Group achieved net sales of USD 58.0 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 120,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world.
Category: Pharmaco
Category: Pharmaco
Keywords: cataract, eye care, generics,

Novartis News

DateNews
2015-11-08Novartis presents new two year data for Cosentyx® showing no progression in joint damage in 84% of psoriatic arthritis p...
2015-11-08New two year data for Novartis' Cosentyx® show sustained response and no progression in spinal damage as shown by x-ray ...
2015-11-04Novartis nominating Elizabeth Doherty and Ton Buechner to the Board of Directors
2015-10-29Novartis Foundation and partners launch new hypertension program in Ghana
2015-10-27Novartis delivered strong core margin expansion (cc) and continued to strengthen the pipeline in Q3; on track for full-y...
2015-10-23Novartis receives positive CHMP opinion for the first IL-17A inhibitor Cosentyx(TM) to treat ankylosing spondylitis and ...
2015-10-21Novartis broadens immuno-oncology pipeline with acquisition of Admune Therapeutics and licensing agreements with XOMA an...
2015-10-15Kenya first country to launch 'Novartis Access', expanding affordable treatment options against chronic diseases
2015-10-10Novartis presents new data showing that the majority of patients are able to maintain clear or almost clear skin with Co...
2015-10-08Long-term efficacy of Gilenya® reinforced by new 'no evidence of disease activity' (NEDA-4) analysis in MS patients over...
2015-10-05Alcon receives FDA Approval for pre-loaded intraocular lens delivery system to treat patients undergoing cataract surger...
2015-10-02FDA accepts Sandoz regulatory submission for a proposed biosimilar etanercept
2015-10-01Novartis announces NEJM publication of secukinumab Phase III data confirming significant efficacy in patients with psori...
2015-09-28Patients with aggressive form of melanoma lived for more than two years on average when taking Novartis therapies Tafinl...
2015-09-27Novartis drug Afinitor® significantly improves progression-free survival in advanced nonfunctional gastrointestinal and ...
2015-09-25Novartis' new heart failure medicine Entresto(TM) recommended by CHMP for EU approval
2015-09-24Novartis launches 'Novartis Access', a portfolio of affordable medicines to treat chronic diseases in lower-income count...
2015-09-24Novartis appoints James E. Bradner, MD as President of the Novartis Institutes for BioMedical Research as Mark Fishman r...
2015-09-18Swissmedic approves Novartis' new heart failure medicine Entresto(TM)
2015-09-07Novartis Foundation healthcare models and disease elimination programs showcased at ECTMIH
2015-09-04Novartis receives EU approval for Farydak®, the first in its class of anticancer agents approved for patients with multi...
2015-09-03Sandoz launches ZarxioTM (filgrastim-sndz), the first biosimilar in the United States
2015-09-03Sandoz launches Zarxio™ (filgrastim-sndz), the first biosimilar in the United States
2015-09-02Novartis receives EU approval for new Revolade® use as first-in-class therapy for patients with severe aplastic anemia
2015-09-01Novartis receives EU approval for Tafinlar® and Mekinist®, first combination approved for patients with aggressive form ...
2015-09-01Novartis announces global partnership with Amgen to develop and commercialize pioneering neuroscience treatments
2015-08-28Novartis continues commitment to go the last mile in effort to eliminate leprosy
2015-08-27Novartis International BioCamp highlights how collaboration and diversity drive innovation and inspires future science l...
2015-08-24FDA expands use of Novartis drug Promacta® to include treatment of children ages 1 and older with chronic immune thrombo...
2015-08-21Novartis acquires all remaining rights to GSK's Ofatumumab to develop treatments for MS and other autoimmune indications
2015-08-20Novartis drug Odomzo® gains EU approval for locally advanced basal cell carcinoma, providing new non-invasive therapy fo...
2015-08-03Novartis completes divestiture of influenza vaccines business to CSL Limited for USD 275 million
2015-07-29Novartis partners with Phase 4 Partners and institutional investors to help create Mereo BioPharma Group Ltd
2015-07-27Novartis Foundation confirms new members of its Board of trustees, including new Chairman Dr. Joerg Reinhardt
2015-07-24FDA approves Novartis drug Odomzo® (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer
2015-07-24Novartis combination therapy Tafinlar® and Mekinist® achieves important EU and US regulatory milestones
2015-07-24Novartis drug Revolade® recommended by CHMP for EU approval to treat patients with severe aplastic anemia, a serious blo...
2015-07-21Novartis delivered solid performance in the second quarter, with strong innovation and progress on new launches
2015-07-16Novartis malaria treatment Coartem® 80/480mg receives WHO prequalification, enabling greater access for patients
2015-06-02Novartis presents new data at EULAR and WCD further demonstrating its leadership in severe long-term inflammatory and sk...
2015-06-01Novartis presents new data at ASCO for Zykadia® and combination of Tafinlar® and Mekinist® in certain NSCLC patients wit...
2015-06-01Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin ly...
2015-05-31Combination of Novartis drugs Tafinlar® and Mekinist® shows significant survival benefit in patients with metastatic mel...
2015-05-27Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA
2015-05-21Novartis drug Afinitor® extended progression-free survival in Phase III trial in advanced gastrointestinal or lung neuro...
2015-05-20Novartis announces two positive US phase III programs in COPD for QVA149 and NVA237
2015-05-08Novartis lung cancer drug Zykadia® gains EU approval, providing new therapy for certain patients with ALK+ NSCLC
2015-04-27Novartis announces Phase III study of Arzerra® met primary endpoint of improved progression-free survival in patients wi...
2015-04-23Novartis delivered sales growth (cc), significant margin expansion (cc) and strong innovation in Q1[1]; now with a more ...
2015-04-21Data at AAN showed Gilenya® high efficacy in achieving 'no evidence of disease activity' in previously-treated highly-ac...
2015-04-21Novartis celebrates 19th annual Community Partnership Day with more than 27,000 associates volunteering in their local c...
2015-04-16Alcon receives FDA approval of new multifocal intraocular lens to treat cataract patients in the United States
2015-04-16Sandoz receives FDA approval for GlatopaTM as the first generic competitor to MS therapy Copaxone® 20mg
2015-04-15Data in The Lancet show Novartis drug Arzerra® plus chlorambucil improved median progression-free survival by 71% in CLL...
2015-04-13Gilenya® data at AAN to highlight Novartis leadership in innovation with new MS assessment methods to benefit patients a...
2015-03-30Novartis accelerates cancer immunotherapy efforts with Aduro Biotech alliance and launch of new immuno-oncology research...
2015-03-30Novartis announces FDA approval for JadenuTM to simplify treatment administration for patients with chronic iron overloa...
2015-03-21Novartis' Cosentyx(TM) two-year data shows sustained effect and favorable safety profile in psoriasis patients
2015-03-20New Novartis data shows Cosentyx(TM) is significantly superior to Stelara® and clears skin (PASI 90) in nearly 80% of ps...
2015-03-17Novartis receives EU approval for Jakavi® in polycythemia vera, first targeted therapy approved for patients with this r...
2015-03-13Novartis to present new late-breaking CosentyxTM data at AAD 2015 showing significant patient benefit in achieving clear...
2015-03-06FDA approves first biosimilar ZarxioTM (filgrastim-sndz) from Sandoz
2015-03-02Novartis announces completion of transactions with GSK
2015-02-27Novartis shareholders approve all resolutions proposed by Novartis Board of Directors
2015-02-27Positive phase II data highlights benefits of Alcon's RTH258 for patients with neovascular (wet) age-related macular deg...
1970-01-01New research identifies link between sub-optimal asthma control across Europe and patient attitudes (PDF)
Brought to you by PharmiWeb.com - Latest Jobs in Pharma
Brought to you by www.pharmiweb.com - Latest Jobs in Pharma.
E_CORE_WARNING Error in file Unknown at line 0: PHP Startup: Invalid library (appears to be a Zend Extension, try loading using zend_extension=opcache.so from php.ini)